Long-Acting Injectables for Schizophrenia: An Effective, Yet Often Underutilized Tool for Rapid Symptom Reduction and Restoration of Function

CMEO Podcast

Premiere Date: Thursday, November 21, 2019

This activity offers CE credit for:

  1. Physicians (CME)
  2. Pharmacists (ACPE)
  3. ABIM (MOC)
  4. Other

Credit Expiration Date: Thursday, December 31, 2020
Note: Credit Is No Longer Available


Christoph U. Correll, MD Christoph U. Correll, MD 
Professor of Psychiatry and Molecular Medicine
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Hempstead, NY
Investigator, Center for Psychiatric Neuroscience
Feinstein Institute for Medical Research
Manhasset, NY
Medical Director, Recognition and Prevention (RAP) Program
The Zucker Hillside Hospital, Department of Psychiatry
Glen Oaks, NY

Statement of Need

Schizophrenia is a serious and debilitating disorder that often poses a considerable challenge to clinicians. While long-acting injectables (LAIs) have emerged as a viable means to address patient nonadherence – often a component of schizophrenia management – clinicians often fail to implement the use of LAIs. Many times this is due to clinicians not being aware of updates such as the introduction of LAIs with increased dosing intervals, knowledge that is an important aspect of narrowing practice gaps in the treatment of this clinically complex disorder. For the first episode in this three-part CMEOcast podcast series on schizophrenia, expert faculty translate the latest data on the impact of LAIs vs. oral therapies in relapse prevention and rapid symptom reduction.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Evaluate the impact of LAIs on quickly stabilizing patients with acute schizophrenia and facilitating seamless long-term maintenance.

The following learning objectives pertain only to those requesting CNE or CPE credit:

  • Evaluate the impact of LAIs on quickly stabilizing patients with acute schizophrenia and facilitating seamless long-term maintenance.

Financial Support

Supported by an educational grant from Alkermes, Inc.

Target Audience

Psychiatrists, nurse practitioners, physician assistants, and pharmacists

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE Credit (Pharmacists):
ACPE CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 0.5 contact hours (0.05 CEUs) Universal Activity Number:
Enduring: 0376-0000-19-055-H01-P

Type: Knowledge-based

ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning Formats
enduring activity

MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.

Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.cmeoutfitters.com/technical.asp.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Correll reports that he receives grants and research support from Janssen Pharmaceutical, Inc.; and Takeda Pharmaceuticals U.S.A., Inc. He is a consultant for Alkermes; Allergan; Angelini Pharma Inc.; Boehringer-Ingelheim; Gedeon Richter; Gerson Lehrman Group, Inc.; Indivior; IntraCellular Therapies; Janssen Pharmaceuticals, Inc.;Johnson & Johnson; LB Pharmaceuticals; Lundbeck; MedAvante-ProPhase, Inc.; Merck & Co., Inc.; Neurocrine Biosciences, Inc.; Noven Pharmaceuticals, Inc.; Otsuka America Pharmaceutical, Inc.; Pfizer Inc.; Recordati; Rovi; Servier; Sumitomo Dainippon Pharma Co., Ltd.; Sunovion Pharmaceuticals Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Teva Pharmaceutical Industries Ltd. He is a stock shareholder (directly purchased): Expert testimony for Bristol-Myers Squibb Company; Janssen Pharmaceutical, Inc.; and Otsuka America Pharmaceutical, Inc. He is Data Safety Monitoring Board member/Chair for Boehringer-Ingelheim; Lundbeck; Rovi; Supernus Pharmaceuticals, Inc.; and Teva Pharmaceutical Industries Ltd.

Tony Graham, MD (peer reviewer) has no disclosures to report.

Mae Ochoa, RPh (peer reviewer) has no disclosures to report.

Kashemi Rorie, PhD (planning committee) has no disclosures to report.

Evan Luberger (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).

This document was last modified on: